Expand AMRX Menu
AMRX MENU

AMRX Latest Press Releases

-- April 24, 2024 --

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Business Wire 8:00 AM

-- April 16, 2024 --

Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine Business Wire 8:00 AM

-- April 10, 2024 --

Amneal to Report First Quarter 2024 Results on May 3, 2024 Business Wire 8:00 AM

-- March 28, 2024 --

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 Business Wire 4:05 PM

-- March 25, 2024 --

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Business Wire 4:05 PM

-- March 1, 2024 --

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results Business Wire 6:00 AM

-- February 27, 2024 --

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 Business Wire 8:00 AM

-- February 13, 2024 --

Amneal to Participate at Upcoming Investor Conference Business Wire 8:00 AM

-- February 8, 2024 --

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application Globe Newswire 4:05 PM

-- February 1, 2024 --

Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts Business Wire 7:00 AM

-- January 31, 2024 --

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024 Business Wire 4:05 PM

-- January 25, 2024 --

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203 Globe Newswire 7:30 AM

-- January 10, 2024 --

Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension Business Wire 8:00 AM

-- January 8, 2024 --

INVESTIGATION ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Long-Term Investors to Contact the Firm PRNewswire 8:00 AM

-- January 4, 2024 --

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023 Business Wire 4:05 PM

-- December 27, 2023 --

AMNEAL INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Investors with Losses to Contact the Firm Globe Newswire 8:30 AM

-- December 21, 2023 --

Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference Business Wire 8:00 AM

-- December 15, 2023 --

Amneal Announces Move to Nasdaq Business Wire 4:05 PM

-- December 7, 2023 --

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS (opicapone) Business Wire 8:00 AM

-- December 1, 2023 --

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules Business Wire 8:00 AM